Multiple sclerosis (MS) is a neurodegenerative disorder that is characterized by repeated inflammatory episodes within the central nervous system. In additional to the relapsing-remitting neurological insults, resulting in the loss of function, a patient with MS always left the residue, troublesome with the symptoms and acute pain.
Like most neurodegenerative disorders, MS gets worse with time as more neurons lose their sheaths and die. CB1 and CB2 receptors influence spasticity and tremors, two common symptoms of MS. Additionally, the contemporary advances in the cannabinoid biology are commencing to support these anecdotal observations. Following the recent clinical trials, cannabis sativa has the modalities of relieving pain, spasms, and spasticity of MS (Leussink, Verena et al., 2012).
The stimulation of the endocannabinoid with the patient with MS, either through the increase of the synthesis or inhibition of the endocannabinoids degradation offers the positive therapeutic potential of the cannabinoid system regulation of levels of the neurodegeneration that happens as a result of inflammatory insults. Further evidence is present in humans in which patient with active MS have a higher concentration of anandamide than those with silent from (Leussink, Verena et al., 2012). Additionally, in approved medical states for THC. In the regulation of MS, the combination of THC and CBD have been developed taking into consideration the synergistic and the reduction of the possible side effects. Double-blind, placebo-controlled attempts have indicated that THC and CBD therapeutically improve several aspects of MS, including pain, mobility factors, bladder problems, and spasticity (Leussink, Verena et al., 2012).
Leussink, V. I., Husseini, L., Warnke, C., Broussalis, E., Hartung, H.-P., & Kieseier, B. C. (2012). Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity. Therapeutic Advances in Neurological Disorders, 5(5), 255–266. http://doi.org/10.1177/1756285612453972